Sodium‐glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of worsening heart failure and mortality in patients with chronic heart failure across the full spectrum of left ventricular ejection fraction (LVEF).17, 18. Here, SLC5A2 is linked to heart failure.